NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
NexImmune, Inc. (Nasdaq: NEXI) announces the establishment of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB), featuring notable experts in immunology and T cell biology. This strategic move aims to enhance the company's AIM nanotechnology platform, which directs antigen-specific T cells for targeted immune responses. Jerry Zeldis, EVP of R&D, emphasized the board's role in refining decisions as NexImmune expands its therapeutic pipeline, especially for its lead programs NEXI-001 and NEXI-002, both in Phase 1/2 clinical trials.
- Formation of AI & ID SAB to guide strategic expansion.
- Expertise from renowned leaders enhances credibility.
- Potential for improved clinical outcomes through expert advice.
- None
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI & ID SAB is comprised of distinguished academic and industry leaders in the fields of autoimmune and infectious diseases, translational research, immunology and T cell biology.
“As we continue to advance our AIM nanotechnology platform, we are grateful to have the input and guidance of these established experts,” said Jerry Zeldis, NexImmune’s EVP of R&D. “Their combined experience in autoimmune and infectious diseases, translational science and clinical development will help make informed decisions as we expand our pipeline and explore new therapeutic areas.”
NexImmune’s AI and ID SAB members include:
Gerald (Jerry) Nepom, MD, PhD (Chair), Director, Immune Tolerance Network; Member Benaroya Research Institute at Virginia Mason (Seattle); Professor (Affil) Department of Immunology, University of Washington School of Medicine.
David Hafler, MD, William S. and Lois Stiles Edgerly Professor of Neurology; Professor of Immunology and Chairman, Department of Neurology, Yale University School of Medicine; Neurologist-in-Chief, Yale New Haven Hospital; Visiting Scientist, Broad Institute of MIT and Harvard.
Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology), Yale University; Deputy Director, Yale Center for Clinical Investigation; Co-Director, Yale Diabetes Center.
James Krueger, MD, PhD, Chief Executive Officer, Co-director for the Center for Clinical and Translational Science, Senior Attending Physician, D. Martin Carter Professor in Clinical Investigation and Laboratory Head of Investigative Dermatology, The Rockefeller University Hospital.
Robin Robinson, PhD, Chief Scientific Officer, RenovaCare, Inc.; former Director, Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Dept. of Health and Human Services.
Robert Siliciano, MD, PhD, Professor of Infectious Diseases, Johns Hopkins Medical Institute; Investigator, Howard Hughes Medical Institute.
Jeffrey (Jeff) S. Weber, MD, PhD, Deputy Director and Head, Experimental Therapeutics, Co-Director of the Melanoma Research Program, Laura and Isaac Comprehensive Perlmutter Cancer Center at NYU Langone Health; Professor of Medicine, NYU Grossman School of Medicine.
For more information, visit https://neximmune.com/our-company/autoimmune-and-infectious-diseases-sab/
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency, and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company’s product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
Contacts
Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
646.319.3261
crubin@neximmune.com
FAQ
What is the purpose of NexImmune's new Autoimmune and Infectious Disease Scientific Advisory Board?
Who are the notable members of the AI & ID SAB at NexImmune?
What clinical programs are currently under development at NexImmune?
How might the formation of the AI & ID SAB impact NexImmune's future?
